Ten year prostate cancer trial proves optimal treatment duration
Results from Australia’s and New Zealand’s biggest cancer trial have identified the best treatment regime for men suffering from newly-diagnosed aggressive but localised prostate cancer.
The RADAR study, run through TROG Cancer Research, compared the use of hormone treatment (longer versus short-term use) coupled with radiation therapy.
This trial enrolled 1,071 men with locally-advanced prostate cancer at 23 treatment centres across Australia and New Zealand, who were monitored over a 10-year period.
The results of this longitudinal study were recently published in the prestigious journal, The Lancet Oncology.
During the trial all men received six months of testosterone suppression therapy, using the drug leuprorelin, followed by radiotherapy. Participants were then randomly allocated to have either an additional 12 months of testosterone suppression therapy (18 months in total) or no further treatment.
The trial found that 18 months testosterone suppression therapy option plus radiotherapy emerged as the most effective, compared to the six month time period.
University Conjoint Professor Jim Denham, who headed the landmark trial, said these findings showed a 30 per cent reduction in deaths due to prostate cancer as well as a 40 per cent reduction in cancer spreading (metastases) to other areas of the body.
“We also found that that men who received the 18 months of treatment did not experience more side effects or impaired quality of life factors than those who received the six months of hormone treatment.”
“The confirmation that quality of life in men treated on the RADAR trial was not inferior to quality of life outcomes in Australian men of the same age, 10 years after treatment, came from the 421 men who participated our ‘Life ten years after prostate cancer treatment’ sub-study,” Professor Denham said.
“Around 17,000 Australian men each year are diagnosed with prostate cancer and we are constantly looking at ways to beat this disease which sees so many men go undiagnosed for a long period of time.
“Thanks to this trial men with newly-diagnosed aggressive but localised prostate cancer can be spared the many long-term side effects associated with longer durations of testosterone suppression (28 to 36 months), which have commonly been used in conjunction with radiotherapy around the world.”
The RADAR trial is one of many significant cancer studies conducted through TROG Cancer Research, which is a world-leading clinical trials group, which is based in Newcastle, NSW, Australia.
Seventy-five-year-old Colin Sandeman was one of the men who volunteered to participate in the trial.
“I didn’t even hesitate when my doctor asked if I wanted to participate in this clinical trial. I had the 18 months of hormone treatment and the impact on my life was minimal.”
Today, at the age of 75 he has returned to his normal life. He’s back into sailing and canoeing and tending his beloved bees.
“I don’t think about having prostate cancer now. It’s in the past. I’m normal, and so many other blokes are too – they’re curing a lot of people,” Mr Sandeman said.
Professor Denham is a radiation oncologist at Calvary Mater Newcastle and a Conjoint Professor with the University of Newcastle. He also researches in collaboration with the Hunter Medical Research Institute.
- Partnership will fund new research into preventing healthcare-associated infections
- New dual degree targets growing job opportunities in medical technology field
- New research highlights Australian music’s global export value and strong international success
- 25 Alumni Awards Achievers in 2019
- Checking in on check-ups to help Close the Gap